James L. Tyree - 17 Dec 2021 Form 4 Insider Report for ChemoCentryx, Inc.

Role: Director
Signature: /s/ Susan M. Kanaya, as Attorney-in-Fact
Issuer symbol: N/A
Transactions as of: 17 Dec 2021
Net transactions value: -$817,415
Form type: 4
Filing time: 21 Dec 2021, 17:33:13 UTC
Previous filing: 24 May 2021
Next filing: 06 May 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CCXI	Common Stock	Options Exercise	$315,500	+25,000	+164%	$12.62	40,275	17 Dec 2021	Direct
transaction	CCXI	Common Stock	Options Exercise	$180,250	+12,500	+31%	$14.42	52,775	17 Dec 2021	Direct
transaction	CCXI	Common Stock	Sale	$93,856	-2,800	-5.3%	$33.52	49,975	17 Dec 2021	Direct	F1, F2
transaction	CCXI	Common Stock	Sale	$577,893	-16,634	-33%	$34.74	33,341	17 Dec 2021	Direct	F1, F3
transaction	CCXI	Common Stock	Sale	$641,415	-18,066	-54%	$35.50	15,275	17 Dec 2021	Direct	F1, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CCXI	Stock Option (right to buy)	Options Exercise		-25,000	-100%		0	17 Dec 2021	Common Stock	25,000	$12.62	Direct	F5, F6
transaction	CCXI	Stock Option (right to buy)	Options Exercise		-12,500	-100%		0	17 Dec 2021	Common Stock	12,500	$14.42	Direct	F5, F6

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
F2	Reflects the weighted average sale price of the shares sold. The shares were sold in multiple trades at prices ranging from $33.14 to $34.09 per share. The Reporting Person will provide to the SEC staff, the issuer or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price.
F3	Reflects the weighted average sale price of the shares sold. The shares were sold in multiple trades at prices ranging from $34.15 to $35.14 per share. The Reporting Person will provide to the SEC staff, the issuer or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price.
F4	Reflects the weighted average sale price of the shares sold. The shares were sold in multiple trades at prices ranging from $35.15 to $35.90 per share. The Reporting Person will provide to the SEC staff, the issuer or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price.
F5	As of December 17, 2021, and prior to this transaction, the exercised options were fully vested.
F6	Not applicable.